BCAX

Bicara Therapeutics
$27.81
+$0.79 (+2.92%)Jul 27, 2026
3.6FairMoatMint rating

MoatMint rates Bicara Therapeutics (BCAX) 3.6 out of 10, a research rating of the company's quality, value, growth, momentum and financial health. Its quality rating is 1.1 out of 10.

Key metrics

The numbers that frame BCAX today
Market cap
$1.83B
P/E (TTM)
-11.6
EV / FCF
-12.9
ROIC
-85.5%
Div yield
0%
Debt / equity
0.0
52wk Low
$9.57
52wk High
$30.99

BCAX stock rating

How BCAX scores on quality, value, growth, momentum and financial health
3.6out of 10
Fair overallNeutral business, expensive priceTop 64% of ~5,000 US stocks
QualityPoor1.1/10
GrowthPoor0.5/10
MomentumGreat9.2/10
ValueFair2.4/10
Financial HealthGreat8.7/10

Growth

Revenue and earnings trend for BCAX
RevenueNet income
See the full growth breakdown

Revenue and earnings trends, margins and the multi-year trajectory - free with an account.

Create a free account
Free foreverNo card required
Already a member? Log in

Cash flow & returns

Free cash flow and financial health
Free cash flowNet debt
See the full cash-flow picture

Free cash flow detail, returns on capital and the balance-sheet trend - free with an account.

Create a free account
Free foreverNo card required
Already a member? Log in

Insider trading

Recent insider buying and selling activity
PurchasesSales
Unlock every insider trade

See who is buying and selling, how much, and when - updated as new filings land.

Create a free account
Free foreverNo card required
Already a member? Log in

Frequently asked questions

Plain-English answers about BCAX
Is Bicara Therapeutics a good buy?
Hold. Bicara Therapeutics has excellent momentum, but poor quality makes the setup mixed. Growth looks poor. That could put pressure on the long-term business case. We think Bicara Therapeutics is selling at a very high price.
What is the market capitalization of BCAX?
Bicara Therapeutics's market capitalization is $1.83B.
What is the P/E ratio for BCAX stock?
Bicara Therapeutics's current P/E ratio is -11.6.
What is the 52-week high for BCAX stock?
The 52-week high for Bicara Therapeutics is $30.99. The current close of $27.81 is 10.3% below that high.
What is the 52-week low for BCAX stock?
The 52-week low for Bicara Therapeutics is $9.57. The current close of $27.81 is 190.6% above that low.
Does BCAX stock pay dividends?
Bicara Therapeutics does not currently show a dividend per share in the company data.
What is the Debt / Equity ratio for BCAX?
Bicara Therapeutics's Debt / Equity ratio is 0.